0001544227-21-000007.txt : 20210209 0001544227-21-000007.hdr.sgml : 20210209 20210209163637 ACCESSION NUMBER: 0001544227-21-000007 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Minai-Azary Jennifer Lynn CENTRAL INDEX KEY: 0001844398 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35890 FILM NUMBER: 21607047 MAIL ADDRESS: STREET 1: 110 MILLER AVENUE STREET 2: SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Millendo Therapeutics, Inc. CENTRAL INDEX KEY: 0001544227 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451472564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 110 MILLER AVENUE, SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 BUSINESS PHONE: 734-845-9000 MAIL ADDRESS: STREET 1: 110 MILLER AVENUE, SUITE 100 CITY: ANN ARBOR STATE: MI ZIP: 48104 FORMER COMPANY: FORMER CONFORMED NAME: OvaScience, Inc. DATE OF NAME CHANGE: 20120308 3 1 wf-form3_161290656696722.xml FORM 3 X0206 3 2021-02-01 0 0001544227 Millendo Therapeutics, Inc. MLND 0001844398 Minai-Azary Jennifer Lynn C/O MILLENDO THERAPEUTICS, INC. 110 MILLER AVENUE, SUITE 100 ANN ARBOR MI 48104 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 1.08 2023-08-21 Common Stock 2969.0 D Stock Option (right to buy) 2.69 2024-05-27 Common Stock 989.0 D Stock Option (right to buy) 4.44 2026-01-27 Common Stock 12382.0 D Stock Option (right to buy) 8.47 2026-11-02 Common Stock 12840.0 D Stock Option (right to buy) 16.4 2028-08-23 Common Stock 11160.0 D Stock Option (right to buy) 10.48 2029-01-31 Common Stock 18000.0 D Stock Option (right to buy) 11.59 2029-06-20 Common Stock 7000.0 D Stock Option (right to buy) 7.94 2030-01-30 Common Stock 20000.0 D Stock Option (right to buy) 2.0 2030-05-24 Common Stock 20000.0 D Shares subject to this option are fully vested. Twenty-five percent (25%) of the shares subject to this option vested on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to this option vested on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Fifty percent (50%) of the shares subject to this option vested on December 31, 2020, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. /s/ Jennifer L. Minai-Azary 2021-02-09